Bringing the fundamentals into focus…
Back to Amneal Pharmaceuticals, Inc.
How Amneal Pharmaceuticals, Inc. stacks up
AMRX · against 205 other Healthcare companies of similar size
Valuation
62/ 100
Above the middle of the pack.
Ranked #77 of 206 · scores higher than 62% of peers
Bars: peers in each 10-point band of the valuation score30 peers with a valuation score of 60–69, including AMRX · Click a bar to see the companies
Why valuation scores 62?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its EBITDA yield, which is stronger than most Healthcare peers.
- Free cash flow yield is close to the peer norm. Free cash flow yield: 2.0% vs peer median 0.0%
- Earnings yield is close to the peer norm. Earnings yield: 2.4% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 70% of peers. EBITDA yield: 7.6% vs peer median 4.0%
Metric by metric
Position: dot = AMRX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | AMRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 203 reported | 2.4% | 2.5% | 49% | 30% | |
| EBITDA yieldHigher is better · 205 reported | 7.5% | 4.6% | 75% | 50% | |
| Free cash flow yieldHigher is better · 121 reported | -0.2% | 1.2% | 40% | 20% | |
| Book yieldHigher is better · 204 reported | 0.5% | 23.4% | 3% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around AMRX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 3 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 4 | 10.4B USD | 96 | 64 | |
| 5 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 68 | 12.7B AUD (≈$8.4B) | 65 | 38 | |
| 74 | 28.4B CNY (≈$4.0B) | 63 | 62 | |
| 74 | 25.3B CNY (≈$3.5B) | 63 | 68 | |
| 74 | 10.4B USD | 63 | 70 | |
| 77 | 7.0B USD | 62 | 57 | |
| 77 | 4.7B GBP (≈$6.1B) | 62 | 49 | |
| 79 | 626.0B INR (≈$7.5B) | 61 | 68 | |
| 79 | 10.6B USD | 61 | 64 | |
| 79 | 4.4B CHF (≈$5.1B) | 61 | 47 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score